"The challenge is scale. The market cap is roughly $803.9 million, the stock trades near $2.30, and shares are down 23.9% over the past"
Large drugmakers accelerate biotech dealmaking ahead of the JPM 2026 Healthcare Conference as patent cliffs approach and growth opportunities are pursued. Strategic capital concentrates in radiopharmaceuticals, next-gen GLP-1 therapies, autologous CAR-T, allogeneic cell therapy, and antibody-drug conjugates. ADC Therapeutics operates as a commercial-stage pure-play after major acquisitions reduced remaining standalone options. Zynlonta revenue increased year over year and upcoming LOTIS-5 Phase 3 topline data could expand peak U.S. revenue potential, supported by cash runway into 2028. Allogene Therapeutics develops off-the-shelf allogeneic CAR-T with ALPHA3 interim results showing higher MRD clearance and no major safety signals, alongside a recent capital raise extending runway into 2029.
Read at 24/7 Wall St.
Unable to calculate read time
Collection
[
|
...
]